(Q39584693)

13 September 2017

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs (English)

1 reference

13 September 2017

1 reference

3

1 reference

13 September 2017

B Weigelt

1

1 reference

PubMed ID

21358673

13 September 2017

P H Warne

series ordinal

2

1 reference

PubMed ID

21358673

13 September 2017

language of work or name

English

0 references

publication date

28 February 2011

1 reference

13 September 2017

1 reference

13 September 2017

30

1 reference

13 September 2017

29

1 reference

13 September 2017

3222-3233

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2011.42

13 September 2017

0 references

cites work

Integrated profiling of basal and luminal breast cancers.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Cell line misidentification: the beginning of the end

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

The PIK3CA gene is mutated with high frequency in human breast cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

mTOR signaling and drug development in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Genome remodelling in a basal-like breast cancer metastasis and xenograft

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

mTOR and cancer: many loops in one pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Identification of a novel inhibitor of mitogen-activated protein kinase kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Defining the role of mTOR in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Rare cancer-specific mutations in PIK3CA show gain of function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Exploiting the PI3K/AKT pathway for cancer drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Genetic alterations and oncogenic pathways associated with breast cancer subtypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

PIK3CA mutation associates with improved outcome in breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Three-dimensional culture models of normal and malignant breast epithelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Frequent mutation of the PIK3CA gene in ovarian and breast cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Targeting the phosphoinositide 3-kinase pathway in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

The third dimension bridges the gap between cell culture and live tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

A coding-independent function of gene and pseudogene mRNAs regulates tumour biology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

High frequency of mutations of the PIK3CA gene in human cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Post-translational regulation of PTEN.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

PTEN-deficient cancers depend on PIK3CB.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Unraveling the microenvironmental influences on the normal mammary gland and breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Modeling tissue morphogenesis and cancer in 3D.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

PI3K pathway alterations in cancer: variations on a theme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

PI(3)king apart PTEN's role in cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.42

31 March 2020

Identifiers

DOI

10.1038/ONC.2011.42

1 reference

13 September 2017

1 reference

PubMed ID

21358673